Derivation of functional early gestation decidual natural killer cell subtypes from induced pluripotent stem cells

This study characterizes gestational changes in decidual natural killer (dNK) cell heterogeneity and function, demonstrating that induced pluripotent stem cells can be differentiated into functional, early-gestation-like dNK2 subtypes via TGF{beta} treatment, thereby establishing a novel platform for modeling reproductive diseases and developing cell-based therapeutics.

The Gist

The Big Picture: The "Security Guard" of Pregnancy

Imagine a pregnancy as a high-stakes construction project. The mother's body is the construction site, and the baby (and its placenta) is a new, semi-foreign structure being built right in the middle of it.

To make sure this project succeeds, the body sends in a specialized security team called Decidual Natural Killer cells (dNK). Unlike the "regular" security guards found in your blood (which are ready to attack anything foreign), these pregnancy guards have a very different job. Their main goal isn't to kill; it's to build, repair, and negotiate. They help blood vessels grow to feed the baby and talk to the placenta to make sure everything is going smoothly.

However, if these guards get confused or act too aggressively, the construction project can fail. This leads to miscarriages, preeclampsia (dangerous high blood pressure), or premature birth.

The Problem: We Didn't Have a "Training Manual"

Scientists have known for a while that these pregnancy guards change their behavior as the pregnancy progresses.

• Early Pregnancy: The guards are very gentle, focused on building blood vessels and keeping the peace.
• Late Pregnancy (Term): The guards seem to get "tougher" and more ready to fight, perhaps to help with the final stages of labor.

The problem is that we can't easily study these cells while a woman is pregnant. We can only get them after a baby is born (or after a miscarriage), which means we miss the "live" action. Also, trying to grow these cells in a lab dish is like trying to teach a wild animal to dance; they are very hard to keep alive and make behave like they do in the body.

The Breakthrough: 3D Printing the Guards

This paper is about a team of scientists who figured out how to 3D print these specific pregnancy guards from scratch using stem cells (the body's "blank slate" cells).

Here is how they did it, using a simple analogy:

1. The Blueprint (The Map): First, the scientists took a detailed "map" (single-cell RNA sequencing) of what these guards look like at different stages of pregnancy. They realized there are different "types" or "sub-teams" of guards.

   • Analogy: Imagine the security team has different shifts. The "Early Shift" guards wear blue vests and carry construction tools. The "Late Shift" guards wear red vests and carry batons. The scientists mapped out exactly who wears what and when.

2. The Factory (The Stem Cells): They took human stem cells (which can become anything) and started turning them into blood cells.

3. The Secret Sauce (TGFβ): This is the magic ingredient. The scientists discovered that if they added a specific chemical signal called TGFβ to their lab culture, it acted like a "uniform changer."

   • Analogy: Without the chemical, the cells were like generic security guards. When they added the TGFβ "uniform," the cells transformed into the specific "Early Pregnancy" type (the blue-vested, construction-focused guards).
   • The scientists found that this chemical signal made the cells express the right markers (like a badge saying "I am a pregnancy guard") and start producing the right chemicals (like VEGF, which helps build blood vessels).

4. The Test Drive: Once they had these "printed" guards, they put them to the test.

   • Do they talk right? Yes, they secreted the same helpful proteins as real pregnancy guards.
   • Do they fight right? They tested if they would attack a target. Real pregnancy guards are gentle; they don't kill easily. The "printed" guards were also gentle, just like the real ones.
   • Do they change with the chemical? When they added the TGFβ, the printed guards shifted their personality to match the "Early Pregnancy" style perfectly.

Why This Matters

Think of this like finally getting a flight simulator for pregnancy complications.

Before this, if a doctor wanted to understand why a pregnancy failed, they could only look at the wreckage after the crash. Now, with this new method, scientists can:

• Model Diseases: They can take stem cells from a woman who has had recurrent miscarriages, "print" her specific pregnancy guards, and see exactly where her security team is going wrong in a dish.
• Test Drugs: They can test new medicines on these printed guards to see if they can fix the problem without harming the patient.
• Future Therapies: One day, we might be able to grow healthy "security guards" in a lab and give them to a patient to help a struggling pregnancy succeed.

The Bottom Line

The scientists successfully figured out how to grow human pregnancy-specific immune cells in a lab. They discovered that a specific chemical signal (TGFβ) is the key to turning generic stem cells into the "gentle, construction-focused" guards needed for early pregnancy. This gives us a powerful new tool to understand and treat pregnancy complications that have been mysteries for too long.

Technical Summary

1. Problem Statement

Decidual Natural Killer (dNK) cells are critical for successful pregnancy, facilitating implantation, angiogenesis, and trophoblast invasion. However, abnormal dNK function is linked to severe pregnancy complications such as recurrent pregnancy loss, preeclampsia, and preterm birth.

• Knowledge Gaps:
  • dNK heterogeneity is poorly understood across gestation. While single-cell RNA sequencing (scRNA-seq) has identified subtypes (dNK1–dNK4) in the first trimester, their distribution and functional shifts at term (specifically in the Basal Plate vs. Chorioamniotic Membranes) remain unclear.
  • Primary dNK cells are difficult to obtain in large quantities from ongoing pregnancies and are hard to expand in culture, limiting mechanistic studies.
  • Existing in vitro models (e.g., iPSC-derived NK cells) typically generate cytotoxic, peripheral blood-like (PB-NK) phenotypes, lacking the specific non-cytotoxic, pro-angiogenic, and tissue-resident characteristics of early gestation dNK.
  • There is no established protocol to generate functional, early-gestation-like dNK from Induced Pluripotent Stem Cells (iPSCs).

2. Methodology

The study employed a multi-modal approach combining primary tissue analysis, transcriptomics, proteomics, and stem cell differentiation:

• Primary Tissue Characterization:

  • Samples: Human decidual tissues from the first trimester and term (Basal Plate [BP] and Chorioamniotic Membranes [CAM]), plus peripheral blood NK (PB-NK).
  • scRNA-seq Re-analysis: Re-analyzed public datasets (Vento-Tormo et al., Pique-Regi et al.) to define subtype-specific markers and map term dNK subtypes (dNK1, dNK2, dNK3, dNKp).
  • Flow Cytometry: Validated surface marker expression (CD56, CD16, CD9, CD69, CD39, KIR2DL1, CD18, CD103) and quantified subtype proportions.
  • Functional Assays: Measured degranulation (CD107a), cytokine secretion (IFN$\gamma$, TNF$\alpha$, GM-CSF), and cytotoxicity against JEG3 choriocarcinoma cells.
  • Secretome Profiling: Used SomaScan aptamer-based proteomics (7K panel) to compare secreted proteins across PB-NK, first-trimester dNK, and term dNK.

• iPSC Differentiation Protocol:

  • Differentiated human embryonic stem cells (hESC) and iPSCs into NK cells using a modified spin-embryoid body (EB) method followed by expansion with IL-2 and IL-15.
  • Intervention: Tested the effect of TGF$\beta$, CXCL12, and hypoxia (5% O$_2$) during the expansion phase to mimic the decidual niche.
  • Characterization: Applied scRNA-seq, flow cytometry, secretome profiling, and functional assays to the resulting iPSC-dNK (with and without TGF$\beta$ treatment).

3. Key Contributions

1. First Comprehensive Term dNK Map: Defined the heterogeneity of dNK at term, revealing distinct subtype compositions between the Basal Plate (BP) and Chorioamniotic Membranes (CAM).
2. Novel iPSC-dNK Protocol: Established the first reproducible protocol to differentiate iPSCs into functional dNK that mimic the early gestation phenotype.
3. TGF$\beta$ as a Critical Driver: Identified TGF$\beta$ as the key factor in shifting iPSC-derived NK cells toward a dNK2-dominant, early-gestation phenotype, characterized by specific surface markers and secretory profiles.
4. Secretome Atlas: Generated the first untargeted proteomic secretome profile of primary dNK across gestation, identifying specific angiogenic and immunomodulatory proteins unique to early gestation.

4. Key Results

A. Primary dNK Heterogeneity Across Gestation

• Subtype Shifts:
  • First Trimester: Dominated by dNK2 (~45%) and dNK1.
  • Term BP: Dominated by dNK3 (~71%), with reduced dNK2.
  • Term CAM: Dominated by dNK2 (~57%), similar to first trimester.
• Phenotypic Changes:
  • Inhibitory Markers: CD9, CD39, and KIR2DL1 (associated with dNK1/dNK2) were significantly reduced at term compared to the first trimester.
  • Activating Markers: CD18 and CD103 (associated with dNK3) were significantly upregulated at term.
  • Function: Term dNK showed higher degranulation (CD107a) in response to PMA/I but failed to induce apoptosis in JEG3 target cells, unlike first-trimester dNK and PB-NK.
• Secretome: First-trimester dNK uniquely secreted high levels of pro-angiogenic factors (VEGF, PLGF, IL-6). These levels were significantly reduced in term dNK (BP and CAM), which resembled PB-NK secretomes more closely.

B. iPSC-Derived dNK (iPSC-dNK) Characterization

• Differentiation: The protocol yielded CD45+CD56+CD16- cells. Without TGF$\beta$, cells were transcriptionally similar to dNK but lacked specific subtype enrichment.
• TGF$\beta$ Effect: Treatment with TGF$\beta$ during expansion:
  • Transcriptome: Shifted the population to 86% dNK2 (vs. 32% in untreated). Upregulated dNK2 marker ZNF683 (HOBIT) and TGF$\beta$ signaling pathways.
  • Surface Markers: Significantly increased CD9 (2-fold) and CD103 (90-fold).
  • Secretome: TGF$\beta$-treated iPSC-dNK secreted significantly higher levels of VEGF and PLGF, mirroring the first-trimester dNK profile, whereas untreated iPSC-dNK resembled PB-NK.
  • Function: TGF$\beta$-treated cells showed reduced GM-CSF secretion upon stimulation (a dNK2 trait) and retained cytotoxic capacity similar to primary first-trimester dNK.

C. Functional Validation

• Cytotoxicity: Both untreated and TGF$\beta$-treated iPSC-dNK could kill JEG3 target cells, unlike term primary dNK.
• Phenotype Matching: TGF$\beta$-treated iPSC-dNK most closely resembled first-trimester dNK in terms of secretome (high VEGF/PLGF), surface markers (CD9+), and subtype composition (dNK2-dominant).

5. Significance

• Modeling Reproductive Disease: This study provides a scalable, patient-specific in vitro model (iPSC-dNK) to study the maternal-fetal interface. This is crucial for investigating the mechanisms of preeclampsia, recurrent miscarriage, and preterm birth, which are often linked to dNK dysfunction.
• Therapeutic Potential: The ability to generate functional, early-gestation-like dNK cells opens avenues for cell-based therapies to correct immune imbalances in pregnancy complications.
• Refining dNK Definitions: The study bridges the gap between transcriptomic definitions (scRNA-seq) and functional/proteomic outputs, suggesting that CD9 combined with other markers can serve as a proxy for the dNK2 phenotype.
• Mechanistic Insight: It clarifies that the functional shift in dNK across gestation is driven by a subtype transition (from dNK2-dominant in early gestation to dNK3-dominant in term BP), rather than just a uniform change in the same cell population.

In conclusion, the authors successfully derived functional dNK from iPSCs that recapitulate the unique pro-angiogenic and immunomodulatory features of early gestation dNK, offering a powerful new tool for reproductive biology research and therapeutic development.